{
    "id": "0de300a2-2952-29fb-80ad-7b2cab86e101",
    "indications": "Oxaprozin tablets are indicated: \n                  \n                     For relief of the signs and symptoms of osteoarthritis \n                     For relief of the signs and symptoms of rheumatoid arthritis \n                     For relief of the signs and symptoms of juvenile rheumatoid arthritis",
    "contraindications": "Use the lowest effective dosage for shortest duration consistent with individual patient treatment goals (2.1) OA: 1200 mg (two 600 mg tablets) given orally once a day ( 2.2 , 2.5 , 14.1 ) RA: 1200 mg (two 600 mg tablets) given orally once a day ( 2.3 , 2.5 , 14.2 ) JRA: 600 mg once daily in patients 22 to 31 kg. 900 mg once daily in patients 32 to 54 kg. 1200 mg once daily in patients ≥ 55 kg ( 2.4 , 2.5)",
    "warningsAndPrecautions": "Oxaprozin tablets USP, 600 mg are yellow, oval shaped, scored, film-coated tablets debossed “C” on one side and “01|70” on the other side supplied in bottles of 100 and 500.\n                  Bottles of 100                                     NDC 55111-170-01 \n                  Bottles of 500                                     NDC 55111-170-05\n                  \n                     Storage\n                  \n                  Keep bottles tightly closed. Store at 20°-25°C (68°-77°F); excursions permitted to 15°-30°C (59°-86°F) [see USP Controlled Room Temperature]. Dispense in a tight, light-resistant container with a child-resistant closure.",
    "adverseReactions": "Oxaprozin tablets are contraindicated in the following patients: \n                  \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to oxaprozin or any components of the drug product [see Warnings and Precautions (5.7, 5.9)\n                        ] \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients [see Warnings and Precautions (5.7, 5.8\n                        )] \n                     In the setting of CABG surgery [see Warnings and Precautions (5.1)]",
    "ingredients": [
        {
            "name": "Oxaprozin",
            "code": "MHJ80W9LRB"
        },
        {
            "name": "starch, corn",
            "code": "O8232NY3SJ"
        },
        {
            "name": "D&C Yellow No. 10",
            "code": "35SW5USQ3G"
        },
        {
            "name": "FD&C Yellow No. 6",
            "code": "H77VEI93A8"
        },
        {
            "name": "hypromelloses",
            "code": "3NXW29V3WO"
        },
        {
            "name": "lactose monohydrate",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "magnesium stearate",
            "code": "70097M6I30"
        },
        {
            "name": "cellulose, microcrystalline",
            "code": "OP1R32D61U"
        },
        {
            "name": "polydextrose",
            "code": "VH2XOU12IE"
        },
        {
            "name": "Polyethylene Glycol, Unspecified",
            "code": "3WJQ0SDW1A"
        },
        {
            "name": "sodium starch glycolate type A potato",
            "code": "5856J3G2A2"
        },
        {
            "name": "titanium dioxide",
            "code": "15FIX9V2JP"
        },
        {
            "name": "triacetin",
            "code": "XHX3C3X673"
        }
    ],
    "organization": "Dr. Reddy's Laboratories Limited",
    "name": "Oxaprozin",
    "effectiveTime": "20241101"
}